BACKGROUND We investigated the use of the gonadotropin-releasing hormone (GnRH) antagonist degarelix in everyday clinical practice using registry data from uro-oncology practices in Germany. METHODS Data were analysed retrospectively from the IQUO (Association for uro-oncological quality assurance) patient registry. Data were prospectively collected from all consecutive PCa patients treated w...

Two forms of gonadotropin-releasing hormone (GnRH), GnRH-I and GnRH-II, are commonly present in mammals. The main hormone controlling reproduction is GnRH-I acting through its receptor (GnRHR-I), whereas the function of GnRH-II is unknown. In primates, it has been suggested that GnRH-II is a specific agonist for the structurally distinct GnRHR-II. Here we compared effects of GnRH-I and GnRH-II ...

To the Editor: Leuprolide is a synthetic luteinizing hormone– releasing hormone (LHRH) agonist used in the treatment of advanced prostate cancer. It is available as an immediate-release intramuscular injection, a depot suspension for intramuscular injection, and an extended-release suspension for subcutaneous injection. After a 45-mg dose of subcutaneous leuprolide, 99.1% of patients experience...

The objective of this study was to examine the degradation of short peptides corresponding to modified fragments of human growth hormone-releasing hormone by trypsin. Six analogues of pentapeptide 9-13 of human growth hormone-releasing hormone containing homoarginine, ornithine, glutamic acid, glycine, leucine or phenylalanine residue in position 11, two analogues of hexapeptide 8-13 of human g...

RANKL: Receptor activator of nuclear factorkappa B ligand; PTHrP: Parathyroid Hormone Related Peptide; ACTH: Adrenocorticotropic Hormone; POMC: Pro-Opiomelanocortin; PNES: Paraneoplastic Endocrine Syndrome; OPG: Osteoprotegrin; CS: Cushing’s Syndrome; CLIP: Corticotrophin-Like Intermediate Lobe Peptide; MSH: α-Melanocyte Stimulating Hormone; CLIP: Corticotrophin-Like Intermediate Lobe Peptide; ...

Several in vitro tests, including transcriptome analysis of neural cells, were performed to assess the capacity 39 pesticides act as thyroid hormone disruptors (THD). Although some elicit a cellular response, which interferes with signaling, we found no evidence that they can receptor agonists or antagonists. We conclude nuclear receptors are not common targets THD, and pesticide neurodevelopme...

Gonadotropin-releasing hormone (GnRH) antagonists, which became commercially available from 1999, have been used for the prevention of premature luteinizing hormone (LH) surges in controlled ovarian stimulation for in vitro fertilization or intracytoplasmic sperm injection. This review focuses on the recent literature on the use of GnRH antagonists and provides guidelines for optimal use in lig...

BACKGROUND Endometrial adenocarcinoma usually occurs after menopause, but in 2%-14% of cases, it occurs in young patients (less than 40 years of age) who are eager to preserve their fertility. Its treatment includes hysterectomy, bilateral salpingo-oophorectomy and pelvic lymphadenectomy, and, in some cases, radiation therapy. AIM To describe a case of endometrial adenocarcinoma occurring in ...

Whole-cell patch-clamp and extracellular field recordings were obtained from 450-microns-thick brain slices of infant rats (10-13 days postnatal) to determine the actions of corticotropin-releasing hormone on glutamate- and GABA-mediated synaptic transmission in the hippocampus. Synthetic corticotropin-releasing hormone (0.15 microM) reversibly increased the excitability of hippocampal pyramida...